Physician profile
Paul E Caimano
NPI 1700860376
$4,931.60
in general payments reported to CMS, 2019-2025
25 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $471 · 2021: $638 · 2022: $770 · 2023: $362 · 2024: $650 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $839.03 | 2024-2025 | Xdemvy |
| Allergan, INC. | $756.06 | 2019-2022 | |
| Abbvie INC. | $728.88 | 2022-2025 | Lumigan, Alphagan P, Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $413.21 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $412.43 | 2022-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $319.55 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $261.31 | 2019-2023 | |
| Oyster Point Pharma, INC. | $210.39 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $193.66 | 2022-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $158.21 | 2019-2021 | |
| Ivantis, INC | $96.20 | 2021 | |
| Ani Pharmaceuticals, INC. | $82.36 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $73.30 | 2024-2025 | Tepezza |
| Dompe US, INC. | $56.68 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.55 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $39.46 | 2024 | Omni Surgical System |
| Glaukos Corporation | $39.02 | 2025 | Idosetr |
| Biotissue Holdings INC. | $38.66 | 2021-2022 | |
| Horizon Therapeutics Plc | $34.88 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $24.97 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.44 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.95 | 2021-2022 | |
| Immunocore Limited | $23.75 | 2025 | Kimmtrak |
| Thea Pharma INC. | $22.78 | 2025 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $18.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Caimano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.